Endogenous antigen presentation of MHC class II epitopes through non-autophagic pathways

Frontiers in Immunology

Volumn 6, Issue SEP, 2015, Pages

  Leung, Carol S K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen presentation; Endogenous presentation; Intracellular antigens; MHC class II molecules; Non classical pathways

Indexed keywords

EPITOPE; HEAT SHOCK PROTEIN 90; HEMAGGLUTININ;

ANTIGEN PRESENTATION; IMMUNOTHERAPY; INTERNALIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84946568451     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00464     Document Type: Short Survey

References (48)

1. BikoffE, Birshtein BK. T cell clones specific for IgG2a of the a allotype: direct evidence for presentation of endogenous antigen. J Immunol (1986) 137(1):28-34.
2. Eisenlohr LC, Hackett CJ. Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis. J Exp Med (1989) 169(3):921-31. doi: 10.1084/jem.169.3.921.
3. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A (1989) 86(1):282-6. doi:10.1073/pnas.86.1.282.
4. Jacobson S, Sekaly RP, Bellini WJ, Johnson CL, McFarland HF, Long EO. Recognition of intracellular measles virus antigens by HLA class II restricted measles virus-specific cytotoxic T lymphocytes. Ann N Y Acad Sci (1988) 540:352-3. doi:10.1111/j.1749-6632.1988.tb27096.x.
5. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO. HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol (1989) 63(4):1756-62.
6. Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med (1990) 172(3):947-54. doi:10.1084/jem.172.3.947.
7. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature (1990) 343(6253):74-6. doi:10.1038/343074a0.
8. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature (1991) 353(6345):622-7. doi:10.1038/353622a0.
9. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med (1993) 178(1):27-47. doi:10.1084/jem.178.1.27.
10. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 50(3-4):213-9. doi:10.1007/s002510050595.
11. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, Paharkova-Vatchkova V, et al. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol (2001) 31(5):1485-94. doi:10.1002/1521-4141(200105)31:5 < 1485::AID-IMMU1485 > 3.0.CO;2-A.
12. Muntasell A, Carrascal M, Serradell L, Veelen Pv PV, Verreck F, Koning F, et al. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides. J Immunol (2002) 169(9):5052-60. doi:10.4049/jimmunol.169.9.5052.
13. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol (2005) 23:975-1028. doi:10.1146/annurev.immunol.22.012703.104538.
14. Lich JD, Elliott JF, Blum JS. Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med (2000) 191(9):1513-24. doi:10.1084/jem.191.9.1513.
15. Dani A, Chaudhry A, Mukherjee P, Rajagopal D, Bhatia S, George A, et al. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment. J Cell Sci (2004) 117(Pt 18):4219-30. doi:10.1242/jcs.01288.
16. Mukherjee P, Dani A, Bhatia S, Singh N, Rudensky AY, George A, et al. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J Immunol (2001) 167(5):2632-41. doi:10.4049/jimmunol.167.5.2632.
17. Comber JD, Robinson TM, Siciliano NA, Snook AE, Eisenlohr LC. Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol (2011) 85(13):6453-63. doi:10.1128/JVI.02122-10.
18. Malnati MS, Marti M, LaVaute T, Jaraquemada D, Biddison W, DeMars R, et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature (1992) 357(6380):702-4. doi:10.1038/357702a0.
19. Lechler R, Aichinger G, Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunol Rev (1996) 151:51-79. doi:10.1111/j.1600-065X.1996.tb00703.x.
20. Aichinger G, Lechler RI. Endogenous pathway of class II presentation. Biochem Soc Trans (1995) 23(3):657-60. doi:10.1042/bst0230657.
21. Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol (2013) 25(4):235-46. doi:10.1093/intimm/dxs155.
22. Ceman S, Sant AJ. The function of invariant chain in class II-restricted antigen presentation. Semin Immunol (1995) 7(6):373-87. doi:10.1006/smim.1995.0042.
23. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, et al. Mice lacking the MHC class II-associated invariant chain. Cell (1993) 72(4):635-48. doi:10.1016/0092-8674(93)90081-Z.
24. Fortin JS, Cloutier M, Thibodeau J. Exposing the specific roles of the invariant chain isoforms in shaping the MHC class II peptidome. Front Immunol (2013) 4:443. doi:10.3389/fimmu.2013.00443.
25. Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Mol Cell Proteomics (2012) 11(11):1457-67. doi:10.1074/mcp. M112.019232.
26. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature (1995) 375(6532):603-6. doi:10.1038/375603a0.
27. Sinnathamby G, Eisenlohr LC. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. J Immunol (2003) 170(7):3504-13. doi:10.4049/jimmunol.170.7.3504.
28. Tewari MK, Sinnathamby G, Rajagopal D, Eisenlohr LC. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol (2005) 6(3):287-94. doi:10.1038/ni1171.
29. Reid PA, Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature (1990) 346(6285): 655-7. doi:10.1038/346655a0.
30. Pathak SS, Lich JD, Blum JS. Cutting edge: editing of recycling class II:peptide complexes by HLA-DM. J Immunol (2001) 167(2):632-5. doi:10.4049/jimmunol.167.2.632.
31. Walseng E, Bakke O, Roche PA. Major histocompatibility complex class II-peptide complexes internalize using a clathrin-and dynamin-independent endocytosis pathway. J Biol Chem (2008) 283(21):14717-27. doi:10.1074/jbc. M801070200.
32. Mimura Y, Mimura-Kimura Y, Doores K, Golgher D, Davis BG, Dwek RA, et al. Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing. Proc Natl Acad Sci USA (2007) 104(14):5983-8. doi:10.1073/pnas.0701307104.
33. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 95:1-30. doi:10.1016/S0065-230X(06)95001-5.
34. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 104(31):12837-42. doi:10.1073/pnas.0703342104.
35. Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, et al. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol (2012) 188(8):3851-8. doi:10.4049/jimmunol.1103269.
36. Imai T, Kato Y, Kajiwara C, Mizukami S, Ishige I, Ichiyanagi T, et al. Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells. Proc Natl Acad Sci U S A (2011) 108(39):16363-8. doi:10.1073/pnas.1108372108.
37. Ichiyanagi T, Imai T, Kajiwara C, Mizukami S, Nakai A, Nakayama T, et al. Essential role of endogenous heat shock protein 90 of dendritic cells in antigen cross-presentation. J Immunol (2010) 185(5):2693-700. doi:10.4049/jimmunol.1000821.
38. Callahan MK, Garg M, Srivastava PK. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc Natl Acad Sci U S A (2008) 105(5):1662-7. doi:10.1073/pnas.0711365105.
39. Kunisawa J, Shastri N. Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway. Immunity (2006) 24(5):523-34. doi:10.1016/j.immuni.2006.03.015.
40. Houlihan JL, Metzler JJ, Blum JS. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells. J Immunol (2009) 182(12):7451-8. doi:10.4049/jimmunol.0804296.
41. Rajagopal D, Bal V, Mayor S, George A, Rath S. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules. Eur J Immunol (2006) 36(4):828-41. doi:10.1002/eji.200535326.
42. Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, et al. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res (2014) 2(4):341-50. doi:10.1158/2326-6066.CIR-13-0138.
43. Lepage S, Lapointe R. Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res (2006) 66(4):2423-32. doi:10.1158/0008-5472.CAN-05-2516.
44. Robila V, Ostankovitch M, Altrich-Vanlith ML, Theos AC, Drover S, Marks MS, et al. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. J Immunol (2008) 181(11):7843-52. doi:10.4049/jimmunol.181.11.7843.
45. Hoashi T, Tamaki K, Hearing VJ. The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J (2010) 24(3):916-30. doi:10.1096/fj.09-140921.
46. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol (2006) 177(6):3746-56. doi:10.4049/jimmunol.177.6.3746.
47. Reilly M, Mix D, Reilly AA, Ye XY, Winslow GM. Intercellular transfer of a soluble viral superantigen. J Virol (2000) 74(18):8262-7. doi:10.1128/JVI.74.18.8262-8267.2000.
48. Leung CS, Haigh TA, Mackay LK, Rickinson AB, Taylor GS. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A (2010) 107(5):2165-70. doi:10.1073/pnas.0909448107.